Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV Study of Recombinant Mycobacterium Tuberculosis Fusion Protein in Community Population
NCT05746611Phase 4Completed
- Sponsor
- Zhifei Biological
- Start
- Apr 2023
- Primary completion
- May 2024
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of recombinant mycobacterium tuberculosis fusion protein (EC) in latent tuberculosis infection (LTBI) (2 cohorts), sponsored by Zhifei Biological. Primary endpoints: Diameter of redness or induration at the reaction site at 0 minute, Diameter of redness or induration at the reaction site at 24 hours and 4 more. Started Apr 2023; status: completed.
02
Drugs
recombinant mycobacterium tuberculosis fusion protein (EC)
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on NCT05746611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05746611.